A carregar...
Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxel
Dasatinib is a potent oral tyrosine kinase inhibitor which targets several kinases, including the SRC family kinases. SRC family kinases have been implicated in androgen therapy resistance that often develops in metastatic castration-resistant prostate cancer (mCRPC), which drives the need for non-a...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3601649/ https://ncbi.nlm.nih.gov/pubmed/23516140 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S41667 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|